J Breast Cancer.
2022 Jun;25(3):253-258. 10.4048/jbc.2022.25.e8.
Intravenous Immunoglobulin to Suppress Progression in a Patient With Advanced Breast Cancer
- Affiliations
-
- 1Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
- 2Department of Oncology and Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan
- 3Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan
- 4Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
- KMID: 2530768
- DOI: http://doi.org/10.4048/jbc.2022.25.e8
Abstract
- Intravenous immunoglobulin (IVIG) is used to treat various diseases and has anticancer effects that suppress metastases in animal models of sarcoma and melanoma. However, these effects have been observed in a limited number of clinical cases. We report the case of a patient with metastatic breast cancer in which long-term IVIG treatment stopped disease progression in the absence of salvage chemotherapy. The patient was treated with IVIG for the treatment of immune thrombocytopenia. Surprisingly, the lung and brain metastases were stabilized, and the patient achieved a progression-free interval of 29 months. More cases are needed to investigate and confirm the efficacy of IVIG in solid tumors in the future.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Utility of ABBI (Advanced breast biopsy instrumentation) for Non-palpable Breast Lesions
- The Open Issues Regarding Cyclin-Dependent Kinase 4/6 Inhibitors in the Management of Advanced Breast Cancer
- Eribulin for Advanced Breast Cancer: A Drug Evaluation
- Short Term Effect of Neoadjuvant Therapy with Docetaxel and Adriamycin in Advanced Breast Cancer
- The Highligts of 28th Annual Meeting of San Antonio Breast Cancer Symposium
